GLP-1s didn't break your plan; the missing engagement lever did

The number showing up in your self-funded claims report right now probably has a familiar shape: a GLP-1 line item that wasn't there three years ago, growing fast enough to distort your entire trend. It's the figure CFOs are staring at in renewal prep meetings across every industry, and the instinct is to treat it as a pharmacy problem — tighten the prior-auth criteria, add a step-therapy protocol, maybe carve out the PBM contract. Those are reasonable tactical moves. They are not a strategy.

Here is the more uncomfortable read: the GLP-1 spend is a symptom. The underlying condition is a plan design that, for years, gave your employees no structural reason to engage with their own health until a diagnosis forced the issue. By the time someone is filling a specialty prescription for a metabolic condition, the upstream opportunity — the wellness visit that wasn't scheduled, the chronic-disease flag that wasn't caught at year two instead of year seven — is already gone. The pharmacy claim is just the invoice.

The engagement gap is where the trend line is built

Self-funded employers carry their own claims risk, which means the multi-year trajectory of that trend line is entirely a function of what your enrolled population does or doesn't do with the plan you've given them. And most plan designs, if you're honest about it, are structured to discourage use. High deductibles create a rational reason for employees to skip the preventive visit, avoid the follow-up, and wait until something is serious enough to justify the out-of-pocket hit. That's not a wellness problem. That's a design problem.

The plans we build for self-funded clients are structured around a zero-deductible model — same carrier the employees already know, no disruption to the network, no carrier swap — specifically because removing the financial barrier at the point of care is the mechanism that drives engagement upstream. We consistently see engagement rates around 85% on these plans. That number matters not because it looks good in a slide deck, but because engagement is the only input that actually bends a self-funded claims trend over a three- to five-year renewal window. Wellness programs, biometric screenings, disease-management vendors — none of them work if employees have a deductible-sized reason to opt out.

What the GLP-1 line item is actually telling you

A rising specialty drug trend in a self-funded plan is telling you that conditions are being caught late and managed expensively. That's a utilization story, not a formulary story. You can manage it at the formulary — and you probably should, as a short-term measure — but if the plan design doesn't change, the next expensive drug class will fill the same gap. The diagnosis mix in your claims data three years from now is being shaped right now by whether your employees are engaging with primary and preventive care today. A zero-deductible structure changes that calculus at the point of decision, not at the point of claim.

The savings that follow from that shift are real — clients in comparable situations have seen average premium-equivalent reductions around 20% — but for a self-funded employer, the more important number is the claims trend itself. A lower trend compounds. A higher one does too.

What we'd tell a client this week

If your GLP-1 and specialty spend is the headline in your next renewal conversation, the right question isn't 'how do we manage this drug category.' The right question is: what is our engagement rate right now, and does our current plan design have any structural mechanism to move it? Most employers don't know the answer to either part. That gap — between what the plan is costing and what the plan is actually doing to influence utilization behavior — is exactly the conversation a claims-trend audit opens. It's not a renewal quote. It's a look at the architecture underneath the number you're already worried about. If that conversation sounds useful, it's the one we start with.